Download Full Text (544 KB)

Document Type



• Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders in the United States and is a large cause of disability. Antidepressants take weeks/months to become effective which can lead to noncompliance. Treatment has a high failure rate which increases medical costs and leads to decreased patient outcomes.

• Pharmacogenetic testing is the practice of analyzing genetic differences to predict a patient’s response to medications to improve efficacy and decrease adverse side effects. The purpose of this study was to investigate if pharmacogenetic-guided treatment, specifically in the use of antidepressants in MDD, has resulted in improved patient outcomes. Additionally, the cost effectiveness was also analyzed.

• The review of literature was conducted by systematically searching the online databases PubMed and PsycINFO, and explored studies that compared the current standard of care to pharmacogenetic-guided treatment in adult patients with MDD aged 18-75.

• The results indicated improved compliance and prognosis for patients with MDD using pharmacogenetic-guided treatment versus the current standard of care. Studies also showed cost effectiveness of pharmacogenetic-guided treatment by decreasing medical costs by having fewer clinic visits, less changes in prescriptions, less sick leave taken, and decreased hospital costs.


Physician Assistant Studies

Degree Name

Master of Physician Assistant Studies (MPAS)

First Advisor

Daryl Sieg

Publication Date



Antidepressive Agents -- therapeutic use; Costs and Cost Analysis; Depressive Disorder, Major -- genetics; Depressive Disorder, Major -- drug therapy; Pharmacogenomic Testing; Treatment Outcome


Pharmaceutical Preparations

Pharmacogenetic Testing in the Treatment of Major Depressive Disorder